FDA Approves Amgen's Parsabiv(TM) (Etelcalcetide), First New Treatment In More Than A Decade For Secondary Hyperparathyroidism In Adult Patients On Hemodialysis

THOUSAND OAKS, Calif., Feb. 7, 2017 -- (Healthcare Sales & Marketing Network) -- Amgen (AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Parsabiv™ (etelcalcetide) for the treatment of secondary hyperparathyroidism (HPT) ... Biopharmaceuticals, Endocrinology, FDA Amgen, Parsabiv, Etelcalcetide, hyperparathyroid
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news